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AR antagonists was too low to produce combined AR antagonistic effects at the concentrations found in human serum, although the high
exposure scenario came quite close to measurable effects. Nevertheless, our analysis exposes an explanation gap which can only be
cancers, termed testicular dysgenesis syndrome (TDS).
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ical factor.
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Introduction
In recent years, several countries have experienced
increases in the incidence of cryptorchisms (reviewed by
Main et al. (2010)) and hypospadias (Pierik et al. 2002,
Boisen et al. 2005, Nelson et al. 2005, Nassar et al.
2007), the most frequent congenital malformations in
young boys. The incidence of testicular germ cell
cancers has risen steadily in Caucasian white men
(Chia et al. 2010) and is now the most commonly
diagnosed malignant neoplasm among men of 15–34
years of age.
There are clear regional differences, but factors that fully
explain these trends and differences have remained
elusive. Although alcohol consumption, low birth weight,
premature birth and diets lacking in protein are recognised
risk factors for cryptorchidism and hypospadias, these
alone cannot account for the current disease trends.
Skakkebaek et al. (2001) have proposed that cryptorchid-
isms and hypospadias are part of a syndrome that also
comprises poor semen quality and testicular germ cellSeveral countries have experienced rises in cryptorchidisms, hypo
are largely unknown, but Skakkebaek has proposed that these diso
androgen insufficiency in foetal life. This suggests that antiandroge
linked to these diseases in epidemiological studies. In animal stud
disruptions of male sexual differentiation became apparent when t
values associated with responses in in vitro assays. This prompted u
would produce mixture effects in an in vitro AR antagonism assay
antiandrogenic modalities could not be considered. Two scenarios w
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dias and testicular germ cell cancer. The reasons for these trends
rs form a testicular dysgenesis syndrome and can be traced to
chemicals might contribute to risks, but few chemicals have been
with p,p 0-dichlorodiphenyldichloroethylene, effects typical of
oetal levels of this androgen receptor (AR) antagonist approached
analyse whether the 22 chemicals with AR antagonistic properties
en combined at concentrations found in human serum. Other
e investigated, one representative of average serum levels reported
posures. In both situations, the in vitro potency of the 22 selectedAttribution 3.0 Unported License.
516 A Kortenkamp and othersEpidemiological studies demonstrating associations
between antiandrogenic chemicals and TDS disorders
are few and far between. This complicates an assessment
of the TDS hypothesis, not least because only a limited
range of chemicals have been investigated. Studies of
paternal and maternal pesticide exposures in agricultural
occupational settings have reported associations with
cryptorchidisms and hypospadias; however, due to
their design, they could not pinpoint specific chemicals
(Pierik et al. 2004, Carbone et al. 2006). There is
evidence for associations of diethylstilboestrol (DES)
(Palmer et al. 2009) and polybrominated diphenyl ethers
(Carmichael et al. 2010) with the risk of developing
cryptorchidisms. Associations between testicular germ
cell cancers and exposure to chlordanes, p,p-dichloro-
diphenyldichloroethylene (p,p-DDE) and certain
3,3 0,4,4 0,5-pentachlorobiphenyls (PCBs) have been
detected in several epidemiological studies, but the
magnitude of effects was relatively small (Hardell et al.
2003, 2004, 2006, McGlynn et al. 2008). There are
several reports of associations between phthalate
exposure during pregnancy and changes in AGD (Swan
et al. 2005, Bustamante-Montes et al. 2008, Swan 2008,
Suzuki et al. 2012), but as yet there is no information
whether phthalates are capable of contributing to the
risk of developing cryptorchidisms, hypospadias or testis
cancer. Other chemicals identified as antiandrogens in
animal models or in vitro assays, such as certain azole
pesticides, benzophenones, parabens or synthetic musks
have not been investigated in epidemiological studies.
Of the chemicals for which associations with TDS
disorders have been noted, only certain polybrominated
diphenyl ethers (Stoker et al. 2005) and phthalates (Wine
et al. 1997) are recognised as antiandrogens.
The associations between TDS disorders and individual
chemicals analysed in epidemiological studies are rela-
tively weak, with odds ratios not far above 1. This suggests
that the investigated chemicals, considered in isolation,
do not make a strong contribution to health risks and
that other, as yet unidentified, influences may be at play,
including new and emerging chemicals not yet recognised
as contributing to TDS disorders. Another aspect likely
to increase risk estimates is the reality of combination
effects between several chemical exposures, not addressed
in the available epidemiological studies.
Since antiandrogenicity is central to the TDS
hypothesis, we wondered whether antiandrogens
known to be present in human tissues are sufficiently
potent, and present in sufficiently high levels and
numbers to result in antiandrogenic effects. We com-
bined tissue dosimetry with data sets describing in vitro
AR antagonist potencies of chemicals and measurements
of human tissue levels, and investigated a possible
explanation gap from the perspective of mixture
toxicology. A study of the AR antagonist p,p-DDE (You
et al. 1999) in a developmental toxicity model in the rat
inspired us to take this approach. To our knowledge, this
Reproduction (2014) 147 515–527is the only paper to date that has anchored antiandro-
genic effects in rats to p,p-DDE tissue levels in the foetus.
You et al. (1999) dosed pregnant dams with p,p-DDE (10
and 100 mg/kg per day) from gestational day (GD) 14 to
18, during the male programming window. Effects on
landmarks of male sexual differentiation (changes in
AGD and retained nipples) were only observed at the
higher dose of 100 mg/kg per day. The concentrations of
p,p-DDE measured in the male foetuses on GD15, 17 and
19 reached values between 2 and 7 mmol/l, a concen-
tration range associated with 20–70% AR antagonism in
in vitro AR antagonist assays based on MDA-kb2 cells
(Wilson et al. 2002, Orton et al. 2011) or CHO-K1 cells
(Kojima et al. 2004). The foetal p,p-DDE levels that
resulted from the smaller dose of 10 mg/kg per day to the
dams (0.2–0.35 mmol/l) were too low to produce in vitro
AR antagonism and in fact did not elicit AGD changes or
retained nipples in the study by You et al. (1999) (Fig. 1).
This interesting concordance led us to assess the
magnitude of combined antiandrogenic effects that can
be expected on the basis of published measurements of
the human tissue levels of antiandrogenic chemicals and
their in vitro potency. In approaching this issue, we could
rely on extensive evidence that the joint effects of multi-
component mixtures of in vitro AR antagonists (up to
30 components) can be approximated quite well by using
the mixture assessment concept of dose addition (Birkhoj
et al. 2004, Kjærstad et al. 2010, Ermler et al. 2011, Orton
et al. 2012, 2013). According to the principles of dose
addition, a concentration of p,p 0-DDE associated with
in vitro activity (and accordingly, a foetal concentration
linked with in vivo effects) can be replaced with several
equi-effective fractions of other active chemicals, without
loss of effect. This opened the way for making an attempt
of predicting the combined effects of antiandrogens in
human tissues entirely by modelling, without conducting
the actual mixture experiments.
However, the dose addition principle together with
application of an in vitro AR antagonist assay meant that
we had to restrict our analysis to AR antagonists. The
possible contribution of antiandrogens that operate
through other modes of action, for example phthalates,
could not be taken into account directly, because such
agents are without effect in in vitro AR antagonist assays.
It is therefore not possible to integrate the effects of AR
antagonists and those of chemicals that suppress
foetal androgen synthesis at the level of AR antagonism.
This can only be achieved by conducting in vivo studies,
but considering that only a handful of chemicals have
been evaluated in vivo, exclusive reliance on in vivo
data would have severely limited the scope of our
analysis. The exclusion of phthalates from the analysis
will have to be reflected on carefully when it comes to
assessing the implications of our observations (see
‘Discussion’ section).
To realise the aims of our study, we had to rely
on chemicals for which concentration–response
www.reproduction-online.org
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Dam Foetus
Maternal dose
(mg/kg per day)
10 0.2 No effects
Foetal levels
at GD19 (µM)
Effects measured
in male offspringrelationships for AR antagonism in vitro had been
described in detail. At the same time, information
about human serum or lipid levels had to be available
for each substance. This restriction reduced the range of
chemicals that could be considered for analysis, mainly
because the number of agents identified as in vitro AR
antagonists by far exceeds the number of chemicals for
which tissue level data are also available. For example,
quite a few pesticides were found to be active (Kojima
et al. 2004, Vinggaard et al. 2008, Orton et al. 2011),
but tissue levels are essentially unknown. We utilised
our data base of in vitro AR antagonists (Ermler et al.
2010, 2011, Orton et al. 2011, 2012, 2013) and
retrieved information about human serum or lipid levels
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Figure 1 Illustration of the tissue dosimetric approach by You et al.
(1999). Shown is how the foetal tissue concentrations of p,p 0-DDE
attained through maternal dosing relate to the in vitro AR antagonistic
effects of p,p 0-DDE measured by Orton et al. (2011), bottom graph. The
two vertical arrows in the bottom graph are the two foetal p,p 0-DDE
tissue levels measured at gestational day 19. It can be seen that the
lower maternal dose which was not associated with demasculinising
effects did not give rise to in vitro AR antagonistic effects. In contrast,
the higher maternal dose induced marked demasculinising effects and
gave rise to foetal p,p 0-DDE levels that produced 70% AR antagonistic
effects in vitro.
www.reproduction-online.orgconstruct (Wilson et al. 2002) were routinely maintained in
Leibowitz-15 (L-15) medium (Invitrogen) supplemented
with 10% FCS (Invitrogen) at 37 8C without additional CO2.
We employed a modified version of the original assay protocol
by Wilson as described in Ermler et al. (2010, 2011).
The androgen DHT (0.25 nmol/l) was used as a positive control
and to establish a baseline for co-exposure for testingChemicals
5a-Dihydrotestosterone (DHT, CAS# 521-18-6, O97% purity)
was purchased from Steraloids Ltd, (London, UK) bisphenol-A
(BPA, CAS# 80-05-7,O99%), n-butyl paraben (CAS# 94-26-8,
O99%), n-propyl paraben (CAS# 94-13-3, O99%), perfluoro-
octane sulphonate (tetrabutylammonium salt) (PFOS, CAS#
111873-33-7, O95%), 2,2 0,4,4 0-tetrahydroxybenzophenone
(benzophenone 2, BP2, CAS# 131-55-5), 2-hydroxy-4-methoxy-
benzophenone (benzophenone 3 (BP3), CAS# 131-57-7, 98%),
butylated hydroxyanisole (CAS# 25013-16-5,O98.5%), butylated
hydroxytoluene (CAS# 128-37-8, O99%), and benzo(a)pyrene
(BaP, CAS# 50-32-8) were purchased from Sigma–Aldrich Co
(Dorset, UK). Ethyl paraben (CAS# 120-47-8, 99%) and methyl
paraben (CAS# 99-76-3, 99%) were obtained from Acros
Organics (Loughborough, UK) and PCB 126 (CAS# 57465-28-8),
hexahydrohexamethylcyclopentabenzopyran (galaxolide,
HHCB, CAS# 1222-05-5) and 6-acetyl-1,1,2,4,4,7-hexamethyl-
tetraline (tonalide, AHTN, CAS#1506-02-1) from LGC Promo-
chem (Teddington, UK). 3-Benzylidene camphor (3-BC, CAS#
15087-24-8) was provided by Induchem AG (Volketswil,
Switzerland), 2,20,4,40,6-pentabromodiphenyl ether (BDE100,
CAS# 189084-64-8) by Cambridge Isotope Laboratories, Inc.
(Ibstock, UK),p,p0-dichlorodiphenyldichloroethylene (p,p0-DDE,
CAS# 72-55-9) by Greyhound Chromatography (Birkenhead,
UK) and 4-methylenbenzylidene camphor (4-MBC, CAS#
36861-47-9) by Merck & Co (Hoddeston, UK).
PCB 118 (CAS# 31508-00-6) was obtained from Ultra
Scientific (Teddington, UK). 2,20,3,4,40,50-Hexachlorobiphenyl
(PCB 138, CAS# 35065-28-2), 2,20,4,40,5,50-hexachlorobiphenyl
(PCB 153, CAS# 35065-27-1) and 2,20,3,4,40,5,50-heptachlor-
obiphenyl (PCB 180, CAS# 35065-29-3) were purchased from
Riedel-de-Haen (Dorset, UK). Stock solutions were made by
dissolving the compounds in ethanol (R99.7%, VWR Inter-
national Ltd, Lutterworth, UK). Stock solutions and all dilution
series were stored at K20 8C. All other reagents were obtained
from Sigma–Aldrich Co. or Invitrogen (Paisley, UK).
Cell culture and (anti-)androgenicity assayof AR antagonists from the peer-reviewed literature.
We identified 22 chemicals for which both human tissue
levels and concentration–response relationships for AR
antagonism in vitro were available (Table 1) and assessed
whether measurable combination effects are to be
expected in the MDA-kb2 assay, when AR antagonists
are combined at levels measured in human tissues.of AR antagonists.
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518 A Kortenkamp and othersStatistical concentration–response analysis
Statistical dose response regression analyses were conducted
according to the best-fit approach (Scholze et al. 2001), by
aAdjusted values to avoid domination of the mixture effect. bNo direct
compared with related compounds (BP2 with BP3 and 4-MBC with 3-BTable 1 Tissue levels of each compound for an average and a high expo
Compounds (in order of EC50) Average levels (M) H
Polybrominated diphenyl ether 100 8.12!10K13
Benzophenone 2 7.50!10K10a
Polychlorinated biphenyl 118 7.08!10K10
p,p 0-DDE 1.90!10K10
Benzo(a)pyrene 1.98!10K9
Bisphenol-A 8.76!10K9
Polychlorinated biphenyl 126 1.18!10K9
Galaxolide (HHCB) 7.10!10K10
Polychlorinated biphenyl 138 3.63!10K9
Butylated hydroxyanisole 5.09!10K11
Polychlorinated biphenyl 180 9.74!10K10
Tonalide (AHTN) 1.77!10K10
Benzophenone 3 8.09!10K10
Polychlorinated biphenyl 153 2.13!10K9
Perfluorooctane sulphonate 2.70!10K8
3-Benzylidene camphor 4.81!10K10a
4-Methylbenzylidene camphor 4.54!10K10
Butylated hydroxytoluene 4.99!10K10
n-Butyl paraben 2.46!10K11
n-Propyl paraben 2.34!10K11
Ethyl paraben 2.21!10K11independently fitting various non-linear regression models to
the same data set and selecting the best-fitting model on the
basis of a statistical goodness-of-fit criterion, as described
earlier (Ermler et al. 2010, 2011).
Calculation of mixture effect predictions
Predictions for the combined effects of the test compounds
were made by using concentration addition (CA), generally
under the assumption of ‘non-interaction’ (i.e. each chemical
in the mixture contributes to a combined effect, but without
exacerbating or diminishing the effects of the other com-
ponents). The mathematical and statistical procedures used for
calculating mixture effects according to CA were the same as
those described in Ermler et al. (2011) and Orton et al. (2012).
The calculation of any effect concentration of a mixture under
the hypothesis of CA was carried out using equation 1.
ECx ðmixtureÞZ
Xn
iZ1
pi
ECxi
 !K1
; (1)
where ECxi is the effect concentration of the ith compound in
the mixture that on its own produces the same quantitative
effect x as the mixture and pi the relative proportion of the
corresponding individual concentration present in the total
mixture concentration. The individual effect concentrations
were derived from the concentration–response functions for the
compounds (Fig. 2 and Supplementary Table 1, see section on
Reproduction (2014) 147 515–527supplementary data given at the end of this article) by using
their inverse functional form. The values for pi were developed
from human tissue levels (Supplementary Table 2).
Owing to its mathematical features, the CA concept cannot
et al. (2007) and Karrman et al. (2007a, 2007b)
2!10K8a –a
.86!10K8 Janjua et al. (2004) and Schlumpf et al. (2010)
9!10K10 Conacher et al. (1986)
9!10K10 Darbre et al. (2004)
4!10K11 Darbre et al. (2004)
7!10K11 Darbre et al. (2004)
3!10K10 Darbre et al. (2004)
e levels available, thus the values were estimated from intake levels,e scenario.
levels (M) References
9!10K11 Meneses et al. (1999), Covaci et al. (2002) and Ramos
et al. (2007)
!10K8a,b –a
.83!10K9 Koppen et al. (2002) and Park et al. (2007)
.70!10K9 Galassi et al. (2008)
.55!10K9 Neal et al. (2008)
.28!10K8 Schoenfelder et al. (2002) and Vandenberg et al.
(2007)
.54!10K9 Koppen et al. (2002)
.59!10K8 Hutter et al. (2005) and Schiavone et al. (2010)
.75!10K9 Koppen et al. (2002) and Park et al. (2007)
2!10K10 Conacher et al. (1986)
.21!10K8 Koppen et al. (2002) and Park et al. (2007)
.10!10K9 Hutter et al. (2005) and Schiavone et al. (2010)
0!10K7b Hany & Nagel (1995) and Schlumpf et al. (2010)
K8be used to calculate the effect concentrations associated with
mixture effects that exceed the maximal AR antagonistic effect
of the least efficacious compound present in the mixture. In the
case investigated here, this limitation was introduced by BaP
which showed AR antagonistic effects of a magnitude not
exceeding 70% of the effect seen with DHT, corresponding to
an AR antagonistic effect of 30%. To construct CA prediction
curves that covered the entire range of antagonistic effects, we
assumed that BaP did not contribute to the overall mixture
effect at effect concentrations beyond the 30% effect.
Collection of tissue level data for AR antagonists and
conversion to serum levels as molar concentrations
Data of human tissue levels of AR antagonistic chemicals
were collected and converted to molar concentrations
(Table 1), with an emphasis on European data. To construct
average exposure scenarios, we used averaged values, but for
the assessment of high exposure scenarios we employed the
highest reported values. For the u.v.-filters benzophenone 2 and
4-methylbenzylidene camphor, tissue level data were not
available. To bridge this gap, we assumed that tissue levels
are similar to those of the related compounds benzophenone 3
and 3-BC. We converted human serum levels (ng/ml) to molar
concentrations, but where only adipose tissue levels were
reported, we used the conversion method described for p,p 0-
DDE by Lo´pez-Cervantes et al. (2004) to arrive at estimated
www.reproduction-online.org
AR antagonistic effects would therefore not become
apparent in the MDA-kb2 assay, in which the 22 selected
chemicals were tested at the average molar concen-
trations in human serum.
In the second scenario, we evaluated the expected
joint effects for serum levels equivalent to high
exposures. This time, the sum of serum concentrations
of all compounds (1.1 mmol/l) was only by a factor of
2.6 lower than the total mixture concentration predicted
to produce 10% AR antagonistic effects (ca. 3 mmol/l;
Fig. 3B). With the statistical power afforded by the
MDA-kb2 assay, which is sufficient to demonstrate
the effect magnitudes of 10% (Ermler et al. 2010), this
concentration would still be too low to produce
measurable effects.
Previous mixture studies from our laboratory were
intended to assess the predictability of combination
effects (Ermler et al. 2011, Orton et al. 2012, 2013),
concentrations of the tested chemicals in the presence of 0.25 nM
dihydrotestosterone (DHT). Shown are the best-fitting regression models.
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Mind the gap 519serum concentrations. Conversions of data from serum levels
on a lipid basis (ng/g) to concentrations on a wet basis (ng/ml)
were performed by dividing the levels by a factor of 129.8.
Reported adipose tissue levels were further divided by a factor
of 4.2 to obtain an estimate of the concentration on a lipid
basis. These conversion factors were specifically validated for
p,p 0-DDE (Lo´pez-Cervantes et al. 2004), but in the absence of
similar validated conversion factors for the compounds
considered here, we applied these factors generally to all the100
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Figure 2 Concentration–response relationships for 22 AR antagonistic
chemicals in the MDA-kb2 assay. Cells were exposed to increasing22 selected chemicals.
Results
For the 22 chemicals listed in Table 1, we recorded
concentration–response relationships for AR antagonism
in the MDA-kb2 gene reporter assay (Fig. 2). We utilised
the regression models for these chemicals (Supplementary
Table 1) to predict their combined additive effects (dose
addition) in the MDA-kb2 assay, for two scenarios.
For the first scenario, we modelled average exposures.
Accordingly, Fig. 3A shows the anticipated combination
effects for a mixture with a mixture ratio equalling the
average serum concentrations determined for each of
the 22 chemicals and for multiples of these concen-
trations. AR antagonistic effects can be expected when
the sum of the concentrations of all 22 components
exceeds values higher than about 2.4 mmol/l, a concen-
tration predicted to be associated with a 10% AR
antagonistic effect, IC10 (for details of the mixture ratios
refer to Supplementary Table 2). However, the sum of the
average serum concentrations of all 22 compounds
reaches only 50 nmol/l, which is by a factor of 48 lower
than the predicted IC10 for the combination.
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Figure 3 Predicted AR antagonistic effects in the MDA-kb2 assay for
a mixture ration in proportion to average human serum levels of all
22 AR antagonists (A) and in proportion to high-end serum levels (B).
The combination effects were calculated by using dose addition
(dark grey line) with confidence belts (broken lines) The light grey belts
depict predictions derived from extrapolations beyond the single effects
of benzo(a)pyrene (for details see ‘Materials and methods’ section).
The vertical arrows to the left indicate the sum of the concentrations of
all 22 chemicals in serum, for the two investigated exposure scenarios.
The arrows to the right depict the effect concentrations of the mixture
predicted to be associated with a 10% AR antagonistic effect (IC10).
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mixture that on its own produces the same quantitative
effect x as the mixture) have the same values for all
exposures. It appears that the potency of the selected
chemicals is too low to produce effects at serum levels,
resulting from environmental exposures. Another way of
interpreting our findings would be to say that we did not
consider sufficiently large numbers of environmental
antiandrogens to reach concentration ranges associated
with effects.
Constraints and limitations
This last aspect is a consequence of the constraints
imposed by the lack of the data required to conduct
modelling studies of the kind presented here. There are
several hundred chemicals capable of antagonising the
AR in vitro (Kojima et al. 2004, Vinggaard et al. 2008),
but data about human tissue levels are available only
for a small fraction of these substances. As pointed
out earlier, this limitation is particularly relevant to
the numerous pesticides identified as in vitro AR
antagonists (Kojima et al. 2004, Vinggaard et al. 2008,
Orton et al. 2011). For these reasons, we were unable
to take account of a larger number of chemicals
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Figure 4 Cumulative risk unit summations for the two mixture
predictions depicted in Fig. 2, for average human serum concentra-
tions (A) and high-end levels (B).
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However, in the two scenarios investigated here, this
condition was not fulfilled, because the components
were assumed to be present in proportion to their
concentrations in body fluids. These concentrations are
not correlated to the potency of the mixture components.
It is therefore to be expected that some chemicals, due to
their prevalence and potency, contribute disproportio-
nately to the overall mixture effect, while the impact of
others may be negligible. To visualise this for the two
scenarios assessed here, we calculated the risk units for
each component based on the concentrations present in
a mixture expected to produce a 10% AR antagonistic
effect (Supplementary Table 2). We then produced rank
orders by arranging the risk units according to their
magnitude and generated cumulative plots of the sums
of risk units (Fig. 4).
For both the average and high exposure scenario,
these plots showed that a relatively small number of
mixture components explained the majority of the
predicted combined effect. In the case of the average
exposure scenario (Fig. 4A), the sum of the four largest
risk units (0.016, from BPA, BaP, PFOS and benzophe-
none 2) already amounted to about 80% of the total sum
of risk units (0.021). These four chemicals, together with
those with the next four largest risk units (PCBs 138, 126,
118 and HHCB), explained 95% of the overall combined
effect. Very similar results became apparent for the high
exposure scenario (Fig. 4B), only that the rank order of
the risk units changed. For high serum concentrations,
benzophenone 2 and 3, BPA, PFOS, HHCB, BaP, 3-BC
and 4-MBC together made up 95% of the total sum of
risk units, while the PCBs and p,p 0-DDE contributed very
little to the combined effect in this scenario. These
proportions are close to Pareto’s rule, which states that
w20% of the causal factors determine 80% of the effects.
Discussion
Interpretation of findings
Our calculations show that AR antagonistic combination
effects demonstrable in the MDA-kb2 assay are not
expected to occur when the selected 22 in vitro AR
antagonists are combined at serum concentrations
encountered in European countries, neither at levelsand to achieve this, all chemicals had to be combined
at mixture ratios proportional to their potency. In this
so-called balanced mixture design, the components
contribute in equal measure to the joint effect, because
the toxic unit or risk unit in equation 1, i.e. the ratio of pi
(the relative proportion of the individual concentration
of a component to the total mixture concentration) and
ECxi (the effect concentration of the ith compound in therepresentative of average exposures, nor at high
Reproduction (2014) 147 515–527R
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Alternatively, if the concentrations of the chemicals are
show that four (average exposures) or three (high
Mind the gap 521to be kept at the levels determined in serum, the only
route open to reach the same effect is by increasing the
number of AR antagonistic substances included in the
mixture by a factor of 48. This would bring the number
of mixture components to 1056 (Z22!48). At present,
this many AR antagonists are not known, and we have
doubts whether such numbers will be identified in
human tissues.
However, with the high exposure scenario, we found
that the sum of the serum concentrations was only
2.6-fold lower than the mixture concentration needed
to provoke effects. If we apply the same calculation to
this case, 57 (Z22!2.6) AR antagonists at levels
equivalent to high-end serum concentrations will have
to be combined to achieve a 10% AR antagonistic
mixture effect. This number is closer to the number of
chemicals with known in vitro AR antagonist properties.
Based on these calculations, it can be expected that
problematic situations are more likely to arise from highA second limitation concerns the antiandrogenic
modalities that could be incorporated into our study.
Certain phthalates may contribute to androgen insuffi-
ciency in foetal life, not by blocking the AR as the agents
investigated here, but by suppressing foetal androgen
synthesis (Howdeshell et al. 2008). However, this mode
of action cannot be captured in the MDA-kb2 assay and
co-exposure to phthalates would have little impact on
the endpoint measured in that assay. For this reason, we
could not include phthalates in our calculations.
Modelling of the joint effects of AR antagonists and
phthalates would have required an integration of
combined effects at a higher physiological level,
measurable only in in vivo studies where it has been
shown that certain phthalates and AR antagonists can
work together to affect landmarks of male sexual
differentiation in the rat (Christiansen et al. 2009,
2012). However, it is possible to take account of the
impact of phthalates in a qualitative manner (see below).
Defining conditions when combination effects are
likely to occur
Despite these constraints and limitations, our efforts help
to define conditions when combination effects of
a sufficient magnitude might occur, by applying the
principles of dose addition. We found that the sum
of the average serum concentrations of our selected AR
antagonists was lower by a factor of 48 than the total
mixture concentration anticipated to produce a 10% AR
antagonistic effect. To achieve an effect of such
magnitude, there are two options, both in line with the
principles of dose addition: one possibility is to increase
the concentration of each of the 22 mixture components
48-fold (which is the option represented in Fig. 3A).exposures, but not from average exposure scenarios.
www.reproduction-online.orgexposures) of the 22 chemicals in the mixtures
accounted for 80% of the sum of risk units. This is
equivalent to 19% (average exposures) or 14% (high
exposures) of the chemicals in the mixtures, close to
Pareto’s 20:80 rule. In both cases, more than half of the
mixture components contributed minimally to the sum
of risk units. These chemicals therefore represent ‘ballast’
that bulks out the estimated numbers of chemicals
needed to provoke a combined effect. Although present
in the mixtures, their influence is minimal, mainly
because their potency is too low to make an impact at
the measured serum levels. We note that some
chemicals that constitute this ‘ballast’, especially the
PCBs and p,p 0-DDE, have been the focus of epidemio-
logical studies exploring associations with TDS
disorders. Strikingly, none of the AR antagonists
contributing most to the mixture effect have been
investigated epidemiologically. Application of Pareto’s
rule allows us to correct the above estimated numbers of
chemicals downwards, to 211 (20% of 1056) and 11
(20% of 57) in the case of average and high-end
exposures, respectively, needed to provoke a 10%
antagonistic effect in the MDA-kb2 assay. In the case of
an effect magnitude of 50%, these numbers reduce
to 1126 (20% of 5632) or 48 (20% of 242) for average orThe impact of the magnitude of the AR
antagonistic effect
We have based our predictions on a 10% AR
antagonistic effect, a magnitude that can be captured
with the statistical power afforded by the MDA-kb2 assay
(Ermler et al. 2010). However, we wondered what the
impact on the estimated numbers of mixture com-
ponents would be if stronger antagonistic effects were
demanded, for example 50%. As can be seen from Fig. 3,
for both average and high exposures, the requirement
to achieve a 50% antagonistic effect would increase
the total mixture concentration to about 13 mmol/l, 256
or 11 times higher than the measured serum levels
respectively. With the demand of keeping the concen-
trations the same as those of the 22 chemicals in each
scenario, the required number of mixture components
will then increase to 5632 (Z22!256) in the case of
average exposures, and 242 (Z22!11) for high
exposures, five or four times higher than the numbers
necessary to achieve a 10% antagonistic effect. The
impact of the required effect magnitude is largely driven
by the gradient of the concentration response curve of
the mixture, with steeper gradients lessening the impact
of effect size.
The implications of Pareto’s rule
The cumulative risk unit summations depicted in Fig. 4high exposures respectively.
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Simplifying assumptions and their impact on
our estimates
We had to base our calculations on a number of largely
unproven assumptions which will be discussed here, in
terms of their impact on our estimated antiandrogen
numbers (for a summary see Table 2). Many of the
chemicals considered here undergo conjugation
reactions, yielding conjugates considered to have no
biological activity. These reactions are particularly
relevant to phenolic substances, such as BPA, parabens
and similar chemicals. The literature we drew on to
obtain information about human tissue levels of our
chosen chemicals reported total serum or lipid levels,
without distinguishing free parent compounds from their
levels of contaminants are correlated, i.e. that there are
subjects who experience high exposures to all the 22
chemicals considered here. We acknowledge that this
is a highly unlikely scenario, representative of a worst-
case assumption. However, multiple pollutants are rarely
measured in one and the same human tissue specimen,
and we could not locate literature where the levels of all
of our chosen chemicals were reported together, but
such data would be needed to put the reconstruction of a
high-end exposure scenario on a more solid footing. We
suggest that this issue can be approached by conducting
probabilistic analyses beyond the scope of this study.
Nevertheless, it is clear that our simplifying assumptions
regarding high exposures have driven upwards the
anticipated mixture effects, and downwards the esti-
every likelihood, the dose addition principle also applies
here: it should be possible to replace the biologically
an
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522 A Kortenkamp and othersconjugates. For this reason, we could not take the impact
of conjugation reactions into consideration but quali-
tatively, this is to be expected to reduce the combined
effects of the mixtures and conversely, to increase the
numbers of chemicals required to provoke AR anta-
gonistic effects. Owing to a lack of appropriate data, we
are at present unable to quantitate this impact. Similarly,
it is difficult to factor in the influence of exposure
duration on the strength on AR antagonistic effects.
While exposures in the in vitro assay only last for 24 h,
sensitive foetal tissues come into contact with the
chemicals of interest for much longer periods of time.
As mentioned earlier, the impossibility of taking
account of antiandrogens that exert their effects via
modes of action different from AR antagonism may have
led to underestimations of the number of chemicals
needed to reach critical foetal levels. Without being able
to quantify the impact of, for example phthalates, which
lead to androgen insufficiency by suppressing androgen
synthesis, their influence can at least be considered
qualitatively: their presence will lead to a reduction in
the critical number of AR antagonists.
An absence of data also forced us to make simplifying
assumptions when constructing the high exposure
scenario. The simple combination of high tissue levels,
as done for our calculations, presupposes that high tissue
Table 2 Assumptions that are currently difficult to verify but which have
critical effects.
Assumption
Critical effect magnitude of AR antagonistic effects larger than 10%
Conjugation reactions remove biologically active AR antagonists
Exposure duration of foetal tissues is longer than in the
AR antagonist assay
Only AR antagonists could be considered
High internal exposures are correlated
Serum levels of AR antagonists are similar to those in foetal tissues
Sensitivity of human foetal tissues is comparable to that of the rat
Mutations and similar factors predispose subgroups of the
population to greater sensitivity to AR antagonistsReproduction (2014) 147 515–527active internal foetal dose of p,p0-DDE with equi-effective
impact on the estimated number of AR antagonists necessary to yield
pact on estimated numbers of AR antagonists required to reach
ritical effects
ill increase
ill increase
onger exposure times may increase the effectiveness of AR antagonists,
and decrease the number of chemicals needed to reach critical effects
onsideration of other antiandrogen modalities will decrease the critical
number of chemicals
high exposures to chemicals are not correlated, larger numbers of AR
antagonists will be required to reach critical effects
umbers will increase if foetal levels are lower
the human is more sensitive, estimates of numbers of chemicals to
reach critical effects will decrease
ritical number of AR antagonists will decreasemated number of chemicals.
Implications for extrapolations to physiological
scenarios relevant to humans
For the majority of the in vitro AR antagonists considered
here, data about the ability to produce antiandrogenic
effects in vivo is lacking entirely. For this reason,
reflections about the physiological relevance of our
analysis have to be undertaken with great care, and by
making explicit all relevant assumptions. This exercise
will expose factors that are currently undefined, but may
have a great impact on the extent of antiandrogenic
effects (see the compilation in Table 2).
First, let us apply the scenario investigated thus far to
the tissue dosimetric approach taken by You et al. (1999)
in their analysis of the antiandrogenic effects of p,p-DDE
in the rat. By using the in vitro AR antagonistic data for
p,p 0-DDE reported by Wilson et al. (2002) and Kojima
et al. (2004), it can be shown that antiandrogenic effects
only became manifest when sufficiently high levels of
p,p 0-DDE had accumulated in the male foetus, levels
clearly associated with in vitro AR antagonistic effects. Inwww.reproduction-online.org
boys (Berkowitz & Lapinski 1996, Jensen et al. 2010,
Mind the gap 523fractions of several other AR antagonists, without loss of
effect. Whether this is achievable in the rat (let alone the
human) with the chemicals investigated here is largely
unexplored, but should depend primarily on toxicoki-
netic factors. It is quite conceivable that the doses of
certain in vitro active compounds that have to be
administered singly to pregnant dams to attain foetal
AR antagonistic tissue levels are so high that maternal
toxicity is induced, in which case the in vitro activity of
such chemicals will be irrelevant because it cannot be
expressed in vivo. Nevertheless, in the light of the
available evidence of the behaviour of in vitro AR
antagonists in combination (Birkhoj et al. 2004, Kjærstad
et al. 2010, Ermler et al. 2011, Orton et al. 2012, 2013),
there is no reason to believe that the 22 chemicals
investigated here should not cause antiandrogenicity in
the rat if they were present in the foetus at the
concentrations shown to produce AR antagonistic effects
in vitro in the MDA-kb2 assay. Viewed from the
perspective of tissue dosimetry, in vitro–in vivo extra-
polations lose much of the mystique that is often
attached to them.
If we continue our thought experiment by considering
the rat, the next question to be examined concerns the
relationship between serum levels of AR antagonists and
those in foetal tissues. Again, these relationships are
largely unexplored, but it would be plausible to assume
that the two concentrations are not drastically different,
unless there are processes that lead to the accumulation
in foetal tissues of certain chemicals. The blood–
placenta barrier is another factor to consider, but many
chemicals evaluated here are able to cross this barrier.
It remains to reflect on the critical AR antagonistic
effect magnitude that a foetus is unable to tolerate without
suffering androgen insufficiency. It is presently unknown
whether this is equivalent to a 10% effect or closer to
50%, and will not be known in the foreseeable future.
However, as discussed above, the likely impact depends
on the gradient of the underlying dose–response curves.
Finally, we need to deliberate on the question of the
sensitivity of the human foetus relative to that of the rat
foetus. These sensitivity differences are currently
unknown, but certain assumptions can be made and
their impact can be elaborated. The sensitivity of the
foetus is the factor likely to have the largest impact on
the number of antiandrogens that need to be invoked to
make a case for potentially adverse tissue concen-
trations. If the sensitivity of foetal tissues is by a factor of
only 10 higher than the sensitivity of an in vitro assay
with MDA-kb2 cells, the predicted dose additive curves
in Fig. 3 will shift by one order of magnitude towards
lower concentrations. In the case of the high exposure
scenario investigated here, this would mean that the 22
in vitro AR antagonists together would already show
joint effects if they were present at these levels in
the foetus. Whether this is realistic is at present difficult
to judge, but an answer to this question will depend
www.reproduction-online.orgKristensen et al. 2011a, Snijder et al. 2012), and
exposure to these drugs is surprisingly high. Paracetamol
(acetaminophen) and aspirin were shown to induce
antiandrogenic effects by a mechanism involvingon better information about the relative sensitivities of
rat and human foetuses to AR antagonists. Similar con-
siderations apply to subgroups of the population with
enhanced sensitivity to AR antagonists.
Is there an explanation gap?
Our analysis forces the conclusion that rampant TDS
disorders cannot at present be explained in terms
of average human exposures to 22 AR antagonists
known to be present in human tissues. Their potencies
and their tissue levels are too low to attain AR
antagonistic effects of a critical magnitude. Conversely,
the number of AR antagonists that one would need
to invoke, under the assumption that both their tissue
levels and their potencies are comparable to those of
known AR antagonists present in human tissues, reaches
250–5500 chemicals. The upper estimate even exceeds
the 2000 in vitro AR antagonists estimated on the
basis of quantitative structure–activity relationships to
be in commercial use (Vinggaard et al. 2008).
The picture that emerges in the case of high exposures is
not as clear-cut. Here, between 10 andw250 chemicals
with potencies and tissue levels comparable to known
AR antagonists would be required to attain critical
effects, and clearly these numbers seem to be more
realistic in relation to the number of known AR
antagonists. But even under this scenario, there is
currently an explanation gap because the lower estimate
of about ten chemicals applies to agents that make a large
contribution to a joint effect, according to the Pareto
principle. The identity of such chemicals is currently not
fully known.
It would appear that these explanation gaps can only
be bridged by conjuring up as yet undiscovered high-
potency AR antagonists, or alternatively high exposures
to unknown agents of average potency. Furthermore, it is
clear that it will be difficult to explain TDS disorders
solely on the basis of AR antagonists. Other antiandro-
genic modalities such as suppression of foetal androgen
synthesis (e.g. by phthalates) will also need to be taken
into account. But even if we consider joint effects
between phthalates and known AR antagonists, critical
effect magnitudes may be hard to reach.
With the realisation of the possible human health
consequences of suppressing prostaglandin synthesis in
foetal life, an additional ‘antiandrogenic’ modality has
recently become the focus of attention. Four epidemio-
logical studies have shown that the use of paracetamol
(acetaminophen) and other analgesics in pregnancy is
associated with an increased risk of cryptorchidism insuppression of prostaglandins, agents important for
Reproduction (2014) 147 515–527
of known environmental risk factors even when the
524 A Kortenkamp and othersattributable risks are small. Although such hypothesis-
driven studies confirm some environmental sources
of disease, they offer only fragments of our understanding
of the major causes and mechanisms of chronic diseases.’
Discussion from meeting
Philippe Grandjean (Odense, Denmark): Your provoca-
tive presentation is very interesting and your conclusions
might be valid, but would be more convincing if you
built in a degree of susceptibility. Thus, vulnerability
should also be included in your Monte Carlo model. You
modelled the sensitivity to androgen receptor antagon-
ists as being tenfold higher in utero than suggested by
in vitro assays, but there are possibly also a variety of
factors, particularly on as yet unknown genetic predis-
position, which must be present to explain the gap.
This is a variable which you must consider to determine
if genetic predisposition rather than the number
of chemicals determines the outcome.
A Kortenkamp (Uxbridge, UK): That is a good
suggestion. Rather than modelling, we are trying to
define a framework which will isolate factors that will
make a big difference from those which do not have
such a strong impact. The sensitivity, vulnerability and
predisposition of the subjects will have a massive impact
on the number of chemicals we have to invoke. In this
context, the magnitude of the effect is not as important.
Louis Guillette (Charleston, USA): It has been
emphasised at this meeting that mixtures are important.male sexual differentiation (Kristensen et al. 2011a).
A variety of other endocrine disrupting chemicals have
been identified as being capable of suppressing prosta-
glandin synthesis in vitro (Kristensen et al. 2011b). It
remains to be seen whether consideration of this new
antiandrogenic modality might help to bridge the
explanation gaps that we exposed here, but we note
that in vitro potencies of many prostaglandin-suppressing
endocrine disrupters are higher than those reported for
AR antagonists.
It will be necessary to search for, and identify, new
antiandrogenic chemicals that are present in human
tissues in an ‘exposome’ approach. This requires
systematic and concerted efforts, an area of research
that has been neglected in the past, very much to the
detriment of environmental epidemiology. Stephen
Rappaport’s lament (Rappaport et al. 2012) of the state
of environmental epidemiology also applies to antian-
drogens and the search for explanations of TDS
disorders: ‘. with few exceptions, the identities of
major environmental toxicants and their roles in causing
chronic disease have not been addressed. Given the poor
state of knowledge about health-impairing environ-
mental exposures, epidemiologists pursue narrow
hypotheses that largely skirt disease aetiology in favourStudies in humans, wildlife and laboratory animals show
Reproduction (2014) 147 515–527that multiple endocrine activities are taking place
simultaneously. Earl Gray has examined multiple mod-
alities with antiandrogenic activity and has described
‘something from nothing’ effects due to the summation of
minor events. You should consider what modalities other
than antiandrogenic substances could have oestrogenic
activity. Glucocorticoid signalling might also be
involved. Michael Eisenberg (this volume) described
many isoforms of the androgen receptor (AR). Most
laboratory tests are targeted on single clones, but there is
a marked diversity in the AR in the human population
especially between different ethnic populations.
A Kortenkamp: We have conducted various AR
in vitro antagonist assays and find that the potency is
very comparable with agreement between different
assays. Modalities other than AR antagonism are difficult
to model because it is not clear how these different
modalities result in common mixture effects at a level of
biological organisation further removed from interaction
with receptors. We have taken account of this by
qualifying our estimates with strong provisos. There is
currently no other way of dealing with this.
Shanna Swan (New York, USA): There are many non-
chemical endocrine disrupters such as stress, nutrition,
sleep and lack of exercise. We have seen that in low
stress mothers there is a twofold increased susceptibility
to phthalates in relation to the anogenital distance (AGD)
of the offspring. Some of these multiple non-chemical
factors can act as antiandrogens.
A Kortenkamp: Your point is much appreciated. These
non-chemical factors probably act by altering sensitivity
to chemical compounds and can be taken into account
in our framework by making different assumptions about
the vulnerability of the foetus.
Anne Marie Vinggaard (Søborg, Denmark): Your
estimations of the hazard index might not be valid
because these are based only on AR antagonism. You
have not included chemicals which inhibit testosterone
production and these have an additive effect to AR
antagonism. Also, the IC50 or IC10 values might not be
appropriate for your calculations because they fail to
take account of protein binding when extrapolating from
in vitro to the in vivo situation. For example, the effect of
PAHs has been shown to be more potent in vivo
if protein binding in vitro is considered.
A Kortenkamp: I agree that other modalities are
relevant to the disorders that we see, but it is difficult
to take these into account with our tentative modelling
approach other than by stating the direction in which
the presence of phthalates and other chemicals with
different modes of action will affect our estimates. They
will likely reduce the number of chemicals we need
to invoke. That is currently the only way to take account
of the factors you mentioned because it is impossible
to aggregate the effects of phthalates and AR antagonists
at the tissue level, where we measure the concentrations
www.reproduction-online.org
matters by studying mixtures rather than single
compounds, but the outcome of your in vitro assay
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